One lead asset. One platform. Room to grow.
IMV-M™ leads the way to the clinic at the IND-enabling stage. Behind it, the Cancerlysin™ platform applies the same apoptosis engine to new tumor-selective antigens.
Each program, in detail.
IMV-M™
Wholly ownedLead program. A MUC16×DR5 bispecific that super-clusters death receptors only on MUC16-positive tumor cells, triggering apoptosis. Research cell bank complete; IND-enabling studies underway.
IMV-C
Wholly ownedA second wholly owned Cancerlysin™ directed at gastrointestinal tumors, advancing through preclinical validation.
IMV-5
PartneringA hematologic-malignancy program in discovery, advancing on a partnering track.
How we choose what to build.
Every Cancerlysin™ program is built on a target that clears three criteria.
Clinical validation
A clinically validated antibody, with freedom to operate, has already demonstrated effective tumor targeting against the antigen in prior studies.
Strong tumor expression
The antigen is consistently expressed across a substantial portion of tumors within the target indication.
Selective targeting
Minimal expression in normal tissue, so the apoptotic signal is restricted to the tumor.
Cancerlysin™ platform
A plug-and-play apoptosis engine: any tumor-selective antigen becomes a scaffold for tumor-restricted DR5 super-clustering — without payloads, internalization, or immune activation. New targets are open to partnering.